Lantheus Holdings, Inc. $LNTH Shares Acquired by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund increased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 88.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 60,067 shares of the medical equipment provider’s stock after purchasing an additional 28,138 shares during the period. Illinois Municipal Retirement Fund owned 0.09% of Lantheus worth $3,081,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Assenagon Asset Management S.A. purchased a new stake in Lantheus during the 3rd quarter worth approximately $65,654,000. Polaris Capital Management LLC acquired a new stake in shares of Lantheus in the third quarter worth approximately $32,687,000. Norges Bank purchased a new stake in shares of Lantheus during the second quarter worth approximately $32,631,000. Boston Partners increased its position in shares of Lantheus by 30.5% during the second quarter. Boston Partners now owns 576,362 shares of the medical equipment provider’s stock worth $46,432,000 after purchasing an additional 134,781 shares in the last quarter. Finally, Frontier Capital Management Co. LLC raised its stake in Lantheus by 52.1% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 315,513 shares of the medical equipment provider’s stock valued at $25,828,000 after purchasing an additional 108,060 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Stock Performance

Lantheus stock opened at $69.38 on Monday. The stock has a market cap of $4.60 billion, a price-to-earnings ratio of 29.15 and a beta of -0.08. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49. The firm has a 50 day simple moving average of $66.30 and a 200-day simple moving average of $59.38. Lantheus Holdings, Inc. has a 1-year low of $47.25 and a 1-year high of $111.29.

Analysts Set New Price Targets

LNTH has been the topic of several recent research reports. Truist Financial lifted their target price on shares of Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Weiss Ratings raised shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Finally, Mizuho increased their price objective on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Five analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Lantheus presently has an average rating of “Moderate Buy” and an average target price of $78.00.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.